Evaluating the Effect of Prebiotics in the Rehabilitation of Gut Microbiota After Antibiotic Therapy in Rats

Antibiyotik Tedavisi Sonrası Gut Mikrobiyota Rehabilitasyonunda Prebiyotiklerin Etkisinin Değerlendirilmesi

Rabia Omer[1], Sanaullah Iqbal[1], Bilal Sajid Mushtaq[2], Muhammad Bilal Hussain[3], Mustafa Nadhim Owaid[4,5], Farhan Saeed[3]
Marwa Waheed[3], Mohammad Ali Shariati[6], Muhammad Usman Khan[7], Toheed Ahmad[1]

[1]Department of Food Science and Human Nutrition, University of Veterinary and Animal Sciences, Lahore, Pakistan
[2]State Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, China
[3]Institute of Home and Food Sciences, Government College University, Faisalabad, Pakistan
[4]Department of Heet Education, General Directorate of Education in Anbar, Ministry of Education, Hit, Anbar, Iraq
[5]Department of Ecology, College of Applied Sciences-Hit, University of Anbar, Hit, Anbar, Iraq
[6]Laboratory of Biological Control and Antimicrobial Resistance, Orel State University named after I.S. Turgenev, Orel City, Russia
[7]Department of Energy Systems Engineering, University of Agriculture, Faisalabad, Pakistan

ABSTRACT

The present study evaluated the effect of galacto-oligosaccharides (GOS) on gut microbiota after antibiotic treatment given two times a day. Four groups were made having six rats in each group. G1 was a control group fed on a basal diet. While, the remaining were treated in groups given antibiotic and GOS separately and also in combination as in G2. The dose of antibiotic and GOS was calculated by HED (Human Equivalent Dose) formula. Fecal samples were analyzed at the interval of five days for bacterial population especially *Bifidobacterium* spp., *Lactobacillus* spp. and *Escherichia coli* and total plate count was achieved using selective media. The results indicated that the growth of *Bifidobacterium* spp. and *Lactobacillus* spp. depended on GOS and antibiotic dose. The combination of GOS-Cephalexin is mostly of interest because due to the antibiotic. The results of *Bifidobacterium* spp. and *Lactobacillus* spp. were decreased while on GOS consumption, the growth of such species is increased. The results of G3 showed that the number of colonies of *Bifidobacterium* spp. and *Lactobacillus* spp. was significantly higher than G2 on the 5th day. Furthermore, the recovery rate was faster as compared to other groups. This research suggested that intake of GOS during antibiotic treatment significantly strengthen the microbiota by increasing the population of *Bifidobacterium* spp. and *Lactobacillus* spp. as well as reducing the number of *E. coli* that shows resistance to many antibiotics.

Key Words: *Bifidobacterium*, Cephalexin, *E. coli,* Food Microbiology, Galacto-oligosaccharide, *Lactobacillus*.

ÖZET

Bu çalışma, günde iki kez verilen antibiyotik tedavisinden sonra galakto-oligosakaritlerin (GOS) bağırsak mikrobiyotası üzerindeki etkisini değerlendirmiştir. Her grupta altı fareye sahip dört grup yapıldı. G1 bazal diyetle beslenen bir kontrol grubuydu. Bununla birlikte, kalanlar ayrı ayrı antibiyotik ve GOS verilen gruplarda ve ayrıca G2'deki kombinasyon halinde tedavi edildi. Antibiyotik ve GOS dozu HED (Human Equivalent Doose) formülü ile hesaplandı. Dışkı örnekleri bakteri popülasyonu için beş gün aralığında, özellikle Bifidobacterium spp., Lactobacillus spp. ve seçici ortam kullanılarak Escherichia coli ve toplam plaka sayımı elde edildi. Sonuçlar Bifidobacterium spp. ve Lactobacillus spp. GOS ve antibiyotik dozuna bağlı. GOS-Sefaleksin kombinasyonu antibiyotik nedeniyle çoğunlukla ilgi çekicidir. Bifidobacterium spp. Sonuçları ve Lactobacillus spp. GOS tüketiminde bu tür türlerin büyümesi artarken azalmıştır. G3'ün sonuçları, Bifidobacterium spp. ve Lactobacillus spp. 5. günde G2'den anlamlı derecede yüksekti. Ayrıca, iyileşme oranı diğer gruplara göre daha hızlı olmuştur. Bu araştırma, antibiyotik tedavisi sırasında GOS alımının, Bifidobacterium spp ve Lactobacillus spp popülasyonunu artırarak ve birçok antibiyotiğe direnç gösteren E. coli sayısını azaltarak mikrobiyotayı önemli ölçüde güçlendirdiğini gösterdi.

Anahtar Sözcükler: Bifidobacterium, Cephalexin, E. coli, Gıda Mikrobiyolojisi, Galacto-oligosakarit, Lactobacillus.

ORCI IDs: R.O. 0000-0002-1868-9761, S.I. 0000-0001-8455-8885, B.S.M. 0000-0002-2808-4635, M.B.H. 0000-0002-5885-1284, M.N.O. 0000-0001-9005-4368, F.S. 0000-0001-5340-4015, M.W. 0000-0002-5218-7554, M.A.S. 0000-0001-9376-5771, M.U.K. 0000-0002-2883-714X , T.A. 0000-0002-0887-279X

INTRODUCTION

Human beings and other multicellular organisms have a close alliance with micro-organisms. It is stated that the human gastrointestinal tract consisted of trillions of cells, an estimated number is 10^{14} bacterial cells (1). Immediately, after birth bacteria continue to grow until the first year of life span. Afterward, they remain (2). It is considered that when the gut microbiota is going to be established, higher than 50 diverse phyla and more than 500 bacterial species present in human gut microbiota. However, the exacted amount of that species and variability among individuals is still needed to be categorized (3). These features are highly hooked on a diet, lifestyle as well as host genotype (4,5).

It is true that from the past 80 years antibiotics saved millions of life by destroying pathogens but the drawback of these also killed beneficial bacteria. In 2015, 50,000 deaths occurred just because of antibiotic-resistant pathogens. In 2025, this value has been increased up to 10 million deaths per year worldwide. So, all the above data show that we are reaching the end of an antibiotic era (6). However, due to the excessive use of antibiotics, we have lesser control on pathogens. Eradicating all pathogens due to their variability is impossible. Hence, attention has turned to the gut microbial ecosystem that acts as an "effective barrier" against pathogens (7).

In third world countries, there is an additional use of antibiotics that disrupt the human gut microbiota and leads to various problems. Such as the highest use of amoxicillin and clindamycin leads to antibiotic-associated diarrhea and it is only happening due to an imbalance of microbiome (8). Increased evidence shows that the said drugs persuaded changes in the configuration of normal gut system and cause of various diseases. Many evidences support this statement. For example, broad-spectrum medicines, particularly β-lactam, target the vitamin K producing bacteria (9). Furthermore, they also linked with the inappropriate immune system (10). The solution of all these problems is to manipulate the gut microbiota and it can be managed by the various ways such as modify the resource supply through controlled diet, by the addition of supplements and the use of prebiotics.

Prebiotics can be defined as: "selectively fermented ingredient that results in specific changes, the configuration or activity of the gastrointestinal microbiota providing benefits upon host health". It is an emerging belief that these are beneficial regarding balanced gut micro-organisms. Unlike probiotics, these are easy to ingest. These can be categorized as dietary fiber or indigestible carbohydrates (11). This acidic environment is favorable for the growth of beneficial bacteria such as *Bifidobacterium* spp. and *Lactobacillus* spp. Contrary to it, creates a negative impact on the growth of pathogenic bacteria (12). Hence, the gut microbiota performs a wide variety of metabolic activities that are essential for the host's metabolism.

Prebiotics are vital because they have many beneficial effects on human health. They provide substantial physiological effects depending on the configuration and activities of intestinal microbiota, both in the lumen and at mucosal layer (13). Many types of carbohydrates retain prebiotic properties but have been best accepted for indigestible oligosaccharides, i.e., galacto-oligosaccharides (14,15). The functional food components of prebiotics are GOS (galacto-oligosaccharides), FOS (fructo-oligosaccharides) and gluco and xylo-oligosaccharide (16).

The use of GOS in this research is to manage the gut system by rehabilitation of beneficial bacteria especially *Lactobacillus* spp. and *Bifidobacterium* spp. that is destroyed by the antibiotic treatment.

MATERIALS and METHODS

Chemicals

All the chemicals and materials were analytical grade and purchased from the local market of Lahore, Pakistan otherwise stated below. Moreover, the fecal sample collected through rats and move in laboratory carefully through sample kit. Finally, the microbial analysis of the fecal samples and the colony counting was done in the laboratory of food science and human nutrition.

Laboratory animals

Twenty-four adult albino rats were selected and housed in stainless steel cages in the animal shed at University of Veterinary and Animal Sciences, Lahore. The rats were kept in the environmentally controlled room with a temperature of

24 ± 5 °C, under a 12 h light: 12 h dark cycles and given free access to water and

food. Rats were allowed to acclimatize in the new environment for one week. The experimental procedure used in this research was approved by the University Ethics Committee for Animal Research.

Prebiotic Source

Galacto-oligosaccharide (GOS) was used as a source of prebiotic. The company of Friesland Campina Domo imported Vivinal® GOS powder. It comprises of 97 % dry matter (milk solids) 3 % moisture; 69% galacto-oligosaccharides, 23% lactose, 5% monosaccharides (glucose and galactose) which is the purely high product of galacto-oligosaccharide. It was kept in an airtight bag and stored under the lab of Department of Food Science and Human Nutrition, University of Veterinary and Animal Sciences (UVAS) Lahore.

Experimental Design

Twenty four healthy rats were randomly divided into four groups having six rats in each group. Group G1 was a control normal that was fed on a basal diet while the remaining groups were treated groups. Groups G2 to Group G4 were given cephalexin antibiotic for five days. Moreover, Group G3 was treated with the combination of GOS and antibiotic for five days, but GOS was continued for further fifteen days. In Group G4, firstly antibiotic was given for specific duration and after that GOS was given for the rest period. The amount of GOS and antibiotic was calculated by the Human Equivalent Dose. HED = animal dose in mg/kg x (animal weight in kg/ human weight in kg)$^{0.33.}$ The amount of GOS and antibiotic was 158 mg and 9 mg respectively. The fecal samples were collected from rats at the 5th day time interval and analyzed for bacterial population especially *Bifidobacterium* spp., *Lactobacillus* spp., *E. coli* and total plate count using selective media (17). A half gram of fecal sample was taken into test tubes which were filled with phosphate buffer solution having a (pH 6.8).

Procedure of Bacterial Enumeration

Lactobacillus spp., *Bifidobacterium* spp. and *Escherichia coli* were counted before and after the treatment as indicator organisms. These bacteria were grown on their selective media. *Lactobacillus* selection agar base, Bifidobacterium Agar, modified (De Man, Rogosa and Sharp agar) and (Eosin Methylene Blue gar) respectively. Incubation was done of *Bifidobacterium* spp. in an anaerobic jar while *Lactobacillus* spp., *E. coli* and total plate count in aerobic condition at 37 °C. For an accurate count, the number of colonies per plate should not exceed 300 nor be less than 30 colonies (18).

Statistical Analysis

Statistical analysis was conducted with the Statistical Package for Social Science (SPSS for Windows version 18, SPSS Inc., Chicago, IL, USA). Data were presented as mean ± S.D. The data were analyzed using One-way Analysis of variance (ANOVA). The group differences were compared by the Duncan's Multiple Range Test. The difference was considered significant at $P \leq 0.05$. The interaction was calculated by Two-way Analysis of variance (ANOVA).

RESULTS

Enumeration of Bifidobacterium

The colonies of *Bifidobacterium* spp of four different groups were counted at intervals of 5, 10, 15 and after 20 days. The log value of CFU/ ml of control and treated groups of *Bifidobacterium* spp. are given in table 1.

Table 1 Mean log value of *Bifidobacterium* spp. at different time intervals

Groups	0 day	The 5th day	The 10th day	The 15th day	The 20th day
G1	10.23±0.033[a,A]	10.21±0.022[a,B]	10.25±0.075[a,A]	10.31±0.077[a,A]	10.29±0.064[b,A]
G2	10.32±0.049[a,A]	6.30±0.083[c,D]	6.57±0.055[d,C]	7.39±0.058[c,B]	7.39±0.058[d,B]
G3	10.31±0.043[a,B]	8.22±0.056[b,D]	9.38±0.079[b,C]	10.37±0.060[a,B]	11.28±0.042[a,A]
G4	10.27±0.112[a,A]	6.28±0.061[d,E]	7.37±0.046[d,C]	8.51±0.032[b,C]	9.62±0.048[c,B]

All the values of *Bifidobacterium* spp. at different time intervals are mentioned in log numbers and are means ± standard deviation for six albino rats. The means sharing the same superscript small alphabets in a column are statistically similar to each other, showing the effects of days of four groups. Moreover, means sharing the same superscript Capital alphabets in a row are statistically alike to each other, showing the effect of treatment at the specified time.

The number of colonies of *Bifidobacterium* spp. at 5th day shows that there was a reduction of colonies when antibiotic was given to treated groups. However, less reduction in colonies was observed in G3 because of GOS. The number of *Bifidobacterium* spp. was highly recoverable in G3 shows that GOS consumption from 5th day to 20th day strengthen the gut microbiota. The interaction is less than 0.05 indicated that interaction between time and groups are significant.

Enumeration of Lactobacillus
The colonies of *Lactobacillus* spp. of four groups were counted at intervals of 5, 10, 15 and after 20 days were given in table 2. The interaction is less than 0.05 indicated that interaction between time and groups are significant.

Table 2 Mean log value of *Lactobacillus* spp. at different time intervals

Groups	0 day	The 5th day	The 10th day	The 15th day	The 20th day
G1	10.31±0.071[a,A]	10.30±0.135[a,A]	10.30±0.135[a,A]	10.26±0.107[b,A]	10.31±0.016[b,A]
G2	10.29±0.058[a,A]	6.28±0.119[c,D]	6.47±0.098[d,C]	7. 40±0.083[d,B]	7.40±0.083[d,B]
G3	10.29±0.062[a,C]	8.56±0.057[b,E]	9.26±0.096[b,D]	10.38±0.050[a,B]	11.27±0.038[a,A]
G4	10.27±0.103[a,A]	6.21±0.089[c,D]	7.32±0.048[c,C]	8.50±0.0250[c,B]	8.50±0.025[c,B]

All the values of *Lactobacillus* spp. at different time intervals are mentioned in log numbers and are means ± standard deviation for six albino rats. The means sharing the same superscript small alphabets in a column are statistically similar to each other, showing the effects of days of four groups. Moreover, the means sharing the same superscript Capital alphabets in a row are statistically alike to each other, showing the effect of treatment at the specified time.

On the 5th day, the numbers of colonies were significantly less from zero-day. As well as a lower number of *Lactobacillus* spp. were observed in G2 and G4 that just treated with the antibiotic. Similarly, on the 10th day all the groups were significantly different from each other. Furthermore, when samples were analyzed on the 15th day the G3 has been recovered and at the 20th day, it has been increased from G1. Although, the colonies were high in G4 that given GOS after antibiotic as compared to G2 but still not recovered at the 20th day.

The interaction is less than 0.05 indicated that interaction between time and groups are significant.

Enumeration of Escherichia coli
The log number of colonies of various groups of *E. coli* is mentioned in table 3. Six different replicates were used in the experiment.

Table 3 Mean log value of *E. coli* at different time intervals

Groups	0 day	The 5th day	The 10th day	The 15th day	The 20th day
G1	11.37±0.064[a,A]	11.33±0.098[a,A]	11.33±0.098[a,A]	11.28±0.124[a,A]	11.35±0.063[a,A]
G2	11.37±0.051[a,A]	7.27±0.063[b,D]	7.58±0.043[b,C]	8.26±0.110[b,B]	8.26±0.110[d,B]
G3	11.37±0.061[a,A]	7.27±0.063[b,D]	7.27±0.063[d,D]	8.21±0.072[b,C]	9.28±0.059[c,B]
G4	11.28±0.052[b,A]	7.25±0.079[b,E]	7.43±0.057[c,D]	8.29±0.053[b,C]	9.47±0.080[b,B]

All the values of *E. coli* at different time intervals are mentioned in log numbers and are means ± standard deviation for six albino rats. The means sharing the same superscript small alphabets in a column are statistically similar to each other, showing the effects of days of four groups. Moreover, the means sharing the same superscript Capital alphabets in a row are statistically alike to each other, showing the effect of treatment at the specified time.

This table illustrates that when antibiotic was given to G2 to G3 the number of colonies was significantly decreased from normal. On the 10th day, the G3 has the lowest number because of GOS utilization that started from the 5th day. However, no group was able to many such bacteria's colonies till the 20th day that meets with the control group. The interaction is less than 0.05 indicated that interaction between time and groups are significant.

Total Plate Count Enumeration
The mean log values of Total Plate Count (TPC) in CFU/ml are mentioned in table 4.

Table 4 Mean log value of TPC at different time intervals

Groups	0 day	The 5th day	The 10th day	The 15th day	The 20th day
G1	12.30±0.154[a,A]	12.27±0.105[a,A]	12.27±0.105[a,A]	12.34±0.032[a,A]	12.36±0.067[a,A]
G2	12.36±0.059[a,A]	8.18±0.149[c,D]	8.56±0.057[d,C]	9.20±0.129[d,B]	9.20±0.129[c,B]
G3	12.32±0.046[a,A]	9.26±0.096[b,D]	10.29±0.062[b,C]	11.28±0.042[b,B]	12.31±0.033[a,A]
G4	12.30±0.42[a,A]	8.24±0.071[c,E]	9.41±0.069[c,D]	10.31±0.064[c,C]	11.36±0.045[b,B]

All the values of total plate count (TPC) at different time intervals are mentioned in log numbers and are means ± standard deviation for six albino rats. The means sharing the same superscript small alphabets in a column are statistically similar to each other, showing the effects of days of four groups. Moreover, the means sharing the same superscript Capital alphabets in a row are statistically alike to each other, showing the effect of treatment at the specified time.

Results were counted for four different groups on the 5th day it showed that the healthy group (control) has the highest number of species significantly as compared to other groups. However, G3 has a significantly lower number of colonies from control while greater as compared to G2 and G4. The recovery rate was first observed in G3 on the 20th day while the other treated groups did not rehabilitate their gut microbiota on the same day.

DISCUSSION

Antibiotics influence human health by creating imbalances of microbes present in the human gut. The use of antibiotics in a high number from childhood to adult cause short and long-term consequences for our health [19]. The human gut system can be deviated from the normal system due to antibiotic usage [20]. The purpose of this study was to inquire whether the response of prebiotic dosage after the antibiotic dose is valuable for the recovery of beneficial bacteria such as bifidobacteria and lactobacilli. During the research, the effect of treatments on various types of bacteria like *Bifidobacterium* spp.*, Lactobacillus* spp.*,* Total Plate Count and *E. coli* species were analyzed.

When the effects of the broad-spectrum antibiotic on the gut microbiome were analyzed, it is stated that it definitely affects the gut microbes. Because In Group 2 and Group 4 that were treated with antibiotic treatment for five days the number of *Bifidobacterium* spp. and *Lactobacillus* spp. were significantly reduced from the normal ($p < 0.05$).

It clearly shows that the treatment of antibiotic for the 5th day majorly disturbed the configuration and reduce the diversity of gut microbiota that was concordant with previous studies [21].

In earlier research conducted on 84 newborns (49 newborns were kept in a normal group while remaining were categorized as Intrapartum Antibiotic Prophylaxis (IAP) group) to check the effect of IAP on gut microbiota of infants. This research stated that the newly born babies treated with the antibiotic have a significantly lower number of *Bifidobacterium* spp. (log value= 6.01) as compared to the normal group (log value= 7.80). Decreased vertical transmissions of *Lactobacillus* spp. were also observed in IAP treated mothers [22]. Moreover, another study stated that antibiotic treatment for more than 5 days in infants leads to severe problems such as necrotizing, sepsis, etc. Prolonged treatment also changes the composition of gut microflora by enhancing the Proteobacteria and reducing the colonies of beneficial bacteria such as bifidobacteria [19].

Antibiotics kill some beneficial species, for example, *Bifidobacterium* spp. and *Lactobacillus* spp. After antibiotic treatment the number of colonies reduced. The present study confirms previous data according to which the fecal count of *Bifidobacterium* spp. and *Lactobacillus* spp. is reduced by antibiotic is given for 3 to 7 days [23]. Additionally, the increased resistance and the severe effects of broad-spectrum antibiotics on gut microbiome stated that it must be complemented with such interventions that would help in stimulating the beneficial bacteria after destruction. One such advancement is modifying the diet such as the use of prebiotics, e.g. fructo-oligosaccharides (FOS) and galactooligosaccharides (GOS). They confer many health benefits to the host as well as protection from external and internal pathogens but not *Clostridium difficile* [24,25].

In the present study when G3 were given both antibiotic and prebiotic, then the number of colonies of *Bifidobacterium* spp. and *Lactobacillus* spp. were significantly higher than G2 at 5th day. Furthermore, the recovery rate was faster as compared to other groups.

In Langlands *et al.* study volunteers were given 7.5 g of oligofructose and the same amount of inulin. When results were matched with the normal group it was observed that the number of *Bifidobacterium* spp. and *Lactobacillus* spp. were notably increased from normal [19]. Similarly in another study on a human when treated with 10g of trans-galactooligosaccharides was also mentioned that there was increased number of *Bifidobacterium* spp. by consuming such type of prebiotic and also modify the gut flora by increasing fermentation metabolism in the colon. Moreover, inulin-type fructans when given to mice it also correlated with the above-mentioned studies showing a higher number of bifidobacteria count [25].

When the results of *Lactobacillus* spp. of four groups were studied, it showed different results at different time intervals. On the 5th day, the bacterial colonies of G2 and G4 showed disruption in gut microflora due to antibiotic treatment. However, it showed some difference with G3 as some species of this group high in values due to the consumption of GOS. The results were observed and also calculated the number of colonies at 10th, 15th and 20th day sampling. It was noticed that the results of G3 were significantly same with G1 on 15th day. While G4 also showed some recovery as there number of colonies was greater than G2. It indicated that beneficial bacteria were highly recoverable due to the bifidogenic effect of GOS. Moreover, G2 was not recovered till 20th, but it may be increased after two weeks because according to a study the destruction

is permanent the *Bifidobacterium* spp. count was attained its original position after one month [22].

During antibiotic therapy, it was noted that the utilization of prebiotics (GOS) was helpful in the rehabilitation of microbiota. After the study, it was observed that due to GOS consumption the recovery rate of *Bifidobacterium* spp. and *Lactobacillus* spp. was faster. Researches above also stated that the development of beneficial bacteria like *Bifidobacterium* spp. and *Lactobacillus* spp. can grow fast along with 3 to 4 types of antibiotics [26]. This is because the GOS produce short-chain fatty acids that can reduce inflammation in the colon and enhance the amount of valuable bacteria such as *Bifidobacterium* spp. and *Lactobacillus* spp. [27].

The results of *Bifidobacterium* spp. showed that the groups treated with GOS were recoverable. Recovery rate was faster in G3 that was given GOS with antibiotic as compared to G4. While no recovery was examined in G2 the recovery rate is so much slow at the 20th day it did not meet with microflora of the normal group. On the 5th day, it was observed that demise of microbiome took place with the use of antibiotics when it was compared with G1. However, the reduction of *Bifidobacterium* spp. colonies was also occurred in G3, but bifidobacteria and lactobacilli count were comparatively higher than G2 and G4. We had also checked the results of 10th and 15th day. It was seen that when results were counted at the 15th day the number of bifidobacterial colonies of G3 that were given antibiotic and prebiotics side by side, were significantly same with group G1. It indicated the recovery of probiotic (bifidobacteria and lactobacilli) by using prebiotic (GOS). When a number of colonies were counted on the 20th day, it illustrated that the number of colonies in group 3 was notably higher from normal. On the other hand, G2 had lowest colonies showed that did not recover back to its position till the 20th day.

Two other protocols were also observed as total plate count and *E. coli*. Cephalexin is active against some gram-negative species such as *E. coli*, *Moraxella*, etc [28]. The study indicated that during antibiotic treatment the number of colonies is reduced in group 2. The number of colonies enhanced on 10th, 15th and 20th day in the same group. However, the rising level of *E. coli* was significantly lower in group 3 and group 4 as compared to G2 because these favored with GOS. The previous studies relate with the present research by stated that GOS act as an anti-adhesive agent against *E. coli* and finally suppress their number in microflora [29,30].

When TPC results were counted it also showed that colonies depend on antibiotic and GOS consumption. TPC amount in group 3 was significantly same with group 1 as P value is less than 0.05. Moreover, the total plate count in group 2 was reduced by the use of an antibiotic. Furthermore, the change in microbiota was mainly observed for beneficial species like *Bifidobacterium* spp. and *Lactobacillus* spp. that provide a crucial role in human health. Change in normal flora is usually associated with the usage of GOS and also depend on an antibiotic. While, total plate count was expected to increase on GOS usage and considered to be decreased by the treatment of antibiotic cephalexin. There was no remarkable change observed in *E. coli* species because it shows resistivity 91.7% to cephalexin that belongs to the first generation of cephalosporin [28].

CONCLUSION

Antibiotics are widely used to kill pathogenic bacteria that have adverse effects on human health. It has been observed that antibiotics cause an imbalance of microbes because these are not only targeting the pathogens but also suppress the growth of beneficial bacteria. Beneficial bacteria like *Bifidobacterium* spp. and *Lactobacillus* spp. conquer many benefits for human health. That is why there is a need to rehabilitate these valuable microorganisms, especially after antibiotic treatment. The important approach in this regard is the use of galacto-oligosaccharides (GOS). GOS considered as a functional component of prebiotics. Prebiotics are considered to have a beneficial effect on the disordered microbiota. The overuse of broad-spectrum antibiotic leads to the resistance that is a worldwide issue. So the modification of microbiota is essential that protect against pathogens as well as disease. This study suggested that intake of 8g of GOS by a human during antibiotic treatment significantly strengthen the microbiota by increasing the population of *Bifidobacterium* spp. and *Lactobacillus* spp. as well as put down the number of *E. coli* that shows resistance towards many antibiotics. This study suggested that 8g of GOS strengthen the microbiota imbalanced by 500 mg of antibiotic given two times in a day.

Conflict of interest
No conflict of interest was declared by the authors.

REFERENCES

1. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010, 90(3): 859-904.
2. DuPont H. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther. 2016; 43: 3-10.
3. Rastall R Bacteria in the gut: friends and foes and how to alter the balance. J Nutr. 2004; 134: 2022-6.
4. Hopkins M, Sharp R, Macfarlane G. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut. 2001; 48: 198-205.
5. Zoetendal EG, Akkermans AD, Akkermans-van Vliet WM, de Visser JAG, de Vos WM. The host genotype affects the bacterial community in the human gastronintestinal tract. Microb Ecol Health Dis. 2001; 13: 129-34.
6. Grande-Bretagne. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance; 2014.
7. Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, Tjota MY, Seo G-Y, Cao S, Theriault BR. Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci USA. 2014; 111: 13145-50.
8. McFarland LV 2008. Antibiotic-associated diarrhea: epidemiology, trends and treatment.
9. Shevchuk YM, Pharm D, Conly JM. Antibiotic-associated hypoprothrombinemia. Infect Dis Rep. 1992; 11: 43-6.
10. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, Holt BJ, Hales BJ, Walker ML, Hollams E. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell host & microbe. 2015; 17: 704-15.
11. Macfarlane S, Macfarlane G, Cummings Jt. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther. 2006; 24: 701-14.
12. Sako T, Matsumoto K, Tanaka R. Recent progress on research and applications of non-digestible galacto-oligosaccharides. Int Dairy J. 1999; 9: 69-80.
13. Keeney KM, Finlay BB. Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut. Curr Opin Microbiol. 2011; 14: 92-8.
14. Gibson G, McCartney A, Rastall R. Prebiotics and resistance to gastrointestinal infections. Br J Nutr. 2005; 93: 31-4.
15. Tuohy K, Rouzaud G, Bruck W, Gibson G. Modulation of the human gut microflora towards improved health using prebiotics-assessment of efficacy. Curr Pharm Des. 2005; 11: 75-90.
16. Wasilewski A, Zielinska M, Storr M, Fichna J. Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21: 1674-82.
17. Ladirat SE, Schuren FH, Schoterman MH, Nauta A, Gruppen H, Schols HA. Impact of galacto-oligosaccharides on the gut microbiota composition and metabolic activity upon antibiotic treatment during *in vitro* fermentation. FEMS Microbiol Ecol. 2014; 87: 41-51.
18. Schillinger U, Lücke FK. Antibacterial activity of *Lactobacillus* sake isolated from meat. Appl Environ Microbiol. 1989; 55: 1901-6.
19. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016; 8: 1.
20. Van der Waaij D, Berghuis-de Vries J, Lekkerkerk-Van der Wees J. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg (Lond). 1971; 69: 405-11.
21. Panda S, Casellas F, Vivancos JL, Cors MG, Santiago A, Cuenca S, Guarner F, Manichanh C. Short-term effect of antibiotics on human gut microbiota. PLoS One. 2014; 9: e95476.
22. Corvaglia L, Tonti G, Martini S, Aceti A, Mazzola G, Aloisio I, Di Gioia D, Faldella G. Influence of intrapartum antibiotic prophylaxis for group B *Streptococcus* on gut microbiota in the first month of life. J Pediatr Gastroenterol Nutr. 2016; 62: 304-8.
23. Newton DF, Macfarlane S, Macfarlane GT. Effects of antibiotics on bacterial species composition and metabolic activities in chemostats containing defined populations of human gut microorganisms. Antimicrob Agents Chemother. 2013; 57: 2016-25.
24. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterol Clin North Am. 1995; 108: 975-82.
25. Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against *Clostridium difficile in vitro*. Appl Environ Microbiol. 2003; 69: 1920-7.
26. Brunser O, Gotteland M, Cruchet S, Figueroa G, Garrido D, Steenhout P. Effect of a milk formula with prebiotics on the intestinal microbiota of infants after an antibiotic treatment. Pediatr Res. 2006; 59: 451-6.
27. Scheppach W, Weiler F. The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care. 2004; 7: 563-7.
28. Arslanoglu S, Moro GE, Schmitt J, Tandoi L, Rizzardi S, Boehm G. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J Nutr. 2008; 138: 1091-5.
29. Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic *Escherichia coli* to tissue culture cells. Infect Immun. 2006; 74(12): 6920-8.
30. Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis. 2015; 60(suppl_2): 108-21.